Children's National Hospital · company speakers →
Immunotherapies have transformed the treatment landscape for several malignant hematologic diseases and are emerging as promising options for non-malignant hematologic diseases. Dr. Bollard will discuss T cell Therapies for Patients with Blood Disorders. Cell therapy performs an ever-increasing role to prevent and treat relapse in patients with blood cancers. Outside of T-cell engineering using chimeric antigen receptors and artificial T-cell receptors, T-cell therapies (especially in the BMT setting) have utilized ex vivo expanded antigen-specific T-cells targeting viral antigens and non-viral tumor-associated antigens. The application of antigen-specific T cell therapeutics post BMT is evidenced by donor lymphocyte infusion strategies, selective depletion, and ex vivo expansion of antigen-specific T cells. In this presentation the evolving history of T cell therapies for blood cancers with a specific focus predominantly on lymphomas will be discussed. An overview how antigen-specific T-cell therapy targeting virus and/or tumor associated antigens may contribute to enhanced overall survival especially in the BMT setting and how such approaches have broadening applicability in the field will be reviewed. In addition, the history and development of CD19 CAR T cells will be reviewed from the initial approval in the pediatric setting to the approvals in the NHL setting and comparing the evolving real-world data in the NHL setting to the results observed in the pivotal trials.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →